Karl L. Mettinger, MD, PhD
Striving for Excellence!
Karl Mettinger is the Founder and Principal of Progressive Clinical Partners. Dr.
Mettinger has over 30 years of experience as an executive in the global life
science industry. He has been involved with the successful development, launch
or out-licensing of new therapeutics, including a number of oncology, hematology, cardiovascular and CNS drugs and biologic products approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulatory agencies.
Dr mettinger and Progressive Clinical Partners recently helped Pharmacyclics (PCYC) with data review / processing which facilitated and accelerated filings/approvals of two NDAs under FDA's new Breakthrough Therpetuics Designation (BTD) paradigm. This led to the successful 21B acquisition of the company by Abbvie in May 2015.
Dr. Mettinger served as Medical Director of Hematology and as Deputy General
Manager of the cardiovascular business unit, of Kabi (Pharmacia, now part of Pfizer), Medical Director/ Executive Director atIVAX Corporation(now part of Teva Pharmaceutical Industries Ltd., NASDAQ:TEVA); Chief Medical Officer/ Senior Vice President at SuperGen,(now Otsuka); Chief Medical Officer at Oncolytics Biotech Inc, AB (NASDAQ: ONCY; TSX: ONC). He is co-founder and past President of the Swedish Stroke Society, a 10,000-member stroke research and patient supportorganization. He is also cofounder, President and acting CEO of Cellastra Inc., and Founder & Principal of Progressive Clinical Partners.
Dr.Mettinger received his M.D. from the University of Lund in Sweden and his Ph.D. in Hematology/Neurology from the Karolinska Institutet/ Karolinska University Hospital in Stockholm, where he was an Associate Professor.
For full profile see: